Literature DB >> 22258486

Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage.

Mirko Manetti1, Serena Guiducci, Eloisa Romano, Silvia Bellando-Randone, Maria Letizia Conforti, Lidia Ibba-Manneschi, Marco Matucci-Cerinic.   

Abstract

OBJECTIVE: To determine serum concentrations and tissue expression of matrix metalloproteinase-12 (MMP-12) and their correlation with clinical features in patients with systemic sclerosis (SSc).
METHODS: Serum MMP-12 levels from 72 patients with SSc and 42 healthy volunteers were examined by ELISA. Immunohistochemical expression of MMP-12 was analysed in skin biopsies from 20 patients with SSc and 13 healthy subjects and lung biopsies from three patients with SSc-related interstitial lung disease (ILD) and five controls.
RESULTS: Circulating levels of MMP-12 were significantly increased in patients with SSc compared with healthy controls. Serum MMP-12 levels were significantly higher in both patients with limited cutaneous SSc and those with diffuse cutaneous SSc than in healthy controls, and correlated positively with the extent of skin involvement. MMP-12 levels were raised in SSc patients with ILD compared with patients without ILD, and correlated with severity of lung restriction. Increased serum levels of MMP-12 were also associated with the presence of digital ulcers and severity of nailfold capillary abnormalities. In contrast to almost undetectable MMP-12 expression in healthy skin, MMP-12 was strongly expressed in keratinocytes, dermal endothelial cells, fibroblasts/myofibroblasts and inflammatory cells in the skin of patients with SSc. Affected lung tissue from patients with SSc-related ILD showed strong MMP-12 expression in capillary vessels, inflammatory cells, alveolar macrophages and fibroblasts in the thickened alveolar septa, while faint expression was observed in normal lung tissue.
CONCLUSIONS: MMP-12 levels are increased in patients with SSc and are associated with severity of skin and pulmonary fibrosis and peripheral vascular damage.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22258486     DOI: 10.1136/annrheumdis-2011-200837

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  32 in total

1.  Endothelial cells recruit macrophages and contribute to a fibrotic milieu in bleomycin lung injury.

Authors:  Heather G Leach; Izabela Chrobak; Rong Han; Maria Trojanowska
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

Review 2.  Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis.

Authors:  Vanessa J Craig; Li Zhang; James S Hagood; Caroline A Owen
Journal:  Am J Respir Cell Mol Biol       Date:  2015-11       Impact factor: 6.914

3.  First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects.

Authors:  Khalid Abd-Elaziz; Christine Voors-Pette; Kang-Ling Wang; Sandy Pan; Yisheng Lee; John Mao; Yuhua Li; Benjamin Chien; David Lau; Zuzana Diamant
Journal:  Clin Drug Investig       Date:  2020-12-17       Impact factor: 2.859

Review 4.  Matrix metalloproteinases: a review of their structure and role in systemic sclerosis.

Authors:  Wen-jia Peng; Jun-wei Yan; Ya-nan Wan; Bing-xiang Wang; Jin-hui Tao; Guo-jun Yang; Hai-feng Pan; Jing Wang
Journal:  J Clin Immunol       Date:  2012-07-06       Impact factor: 8.317

Review 5.  Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.

Authors:  Colin Ligon; Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

Review 6.  Regulation and involvement of matrix metalloproteinases in vascular diseases.

Authors:  Matthew Amin; Sathnur Pushpakumar; Nino Muradashvili; Sourav Kundu; Suresh C Tyagi; Utpal Sen
Journal:  Front Biosci (Landmark Ed)       Date:  2016-01-01

7.  Proteomic profiling identifies key differences between inter-stage infants with single ventricle heart disease and healthy controls.

Authors:  Benjamin S Frank; Ludmila Khailova; Lori Silveira; Max B Mitchell; Gareth J Morgan; Elena W Y Hsieh; Michael V DiMaria; Mark Twite; Jelena Klawitter; Jesse A Davidson
Journal:  Transl Res       Date:  2020-10-09       Impact factor: 7.012

8.  Circulating biomarkers of interstitial lung disease in systemic sclerosis.

Authors:  Harpreet K Lota; Elisabetta A Renzoni
Journal:  Int J Rheumatol       Date:  2012-09-03

9.  Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease.

Authors:  Shomi Oka; Hiroshi Furukawa; Kota Shimada; Hiromi Hayakawa; Naoshi Fukui; Naoyuki Tsuchiya; Shigeto Tohma
Journal:  BMC Immunol       Date:  2013-02-14       Impact factor: 3.615

Review 10.  Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.

Authors:  Willis S Bowman; Gabrielle A Echt; Justin M Oldham
Journal:  Front Med (Lausanne)       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.